Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Study sponsor: Can-Fite BioPharma
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-04-15Estimated
Enrollment · participants114Estimated
Source updated2024-07-31Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.